BSX · Full Picture

BOSTON SCIENTIFIC CORP — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 51
    +7.0% revenue (realized); quote_verified
    Boston Scientific reported revenue of $5.44 billion for their June quarter on July 29, up 7.5% over the same period last year.
  2. Guidance / Outlook · Guidance & outlookPriority 37
    2 forward row(s); quote_verified
    Boston Scientific cut its 2026 guidance, with the cut attributed to WATCHMAN weakness, electrophysiology (EP) share losses and delayed margin gains.
  3. Product Safety Recall · UnclassifiedPriority 37
    3 forward row(s); quote_verified
    Boston Scientific has initiated multiple Class II product recalls for cardiac ablation generators and vascular access sheaths.
  4. Competition and Market Share · Competition & market sharePriority 32
    quote_verified
    FMR LLC and Abigail P. Johnson disclosed beneficial ownership of 46,378,258.61 shares of Boston Scientific common stock, representing a 3.1% stake as of June 30, 2026.

Threads by pillar

Revenue & Demand Priority 51 · 1 thread

Guidance & Outlook Priority 37 · 1 thread

Macro & Market Conditions Priority 32 · 1 thread

Unclassified Priority 37 · 1 thread

Expected impact by metric

metricforward netforward grossrealized
revenue——+7.0%